Malik, N. , Hay, J. , Almuhanna, H. N.B., Dunn, K. M., Lees, J., Cassels, J., Li, J., Nakagawa, R., Sansom, O. J. and Michie, A. M. (2023) mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia. Leukemia, 37, pp. 2414-2425. (doi: 10.1038/s41375-023-02043-3) (PMID:37775560) (PMCID:PMC10681897)

Hay, J. et al. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14(23), 6006. (doi: 10.3390/cancers14236006) (PMID:36497487) (PMCID:PMC9735720)

Chantkran, W., Hsieh, Y.-C., Zheleva, D., Frame, S., Wheadon, H. and Copland, M. (2021) Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. Cell Death Discovery, 7, 137. (doi: 10.1038/s41420-021-00496-y) (PMID:34112754) (PMCID:PMC8192769)

Horne, G. et al. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34(7), pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9) (PMID:31925317) (PMCID:PMC7224085)

Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)

Malik, N. , Dunn, K. M., Cassels, J., Hay, J. , Estell, C., Sansom, O. J. and Michie, A. M. (2019) mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. Scientific Reports, 9, 16917. (doi: 10.1038/s41598-019-53141-1) (PMID:31729420) (PMCID:PMC6858379)